Panelists discuss how immunoglobulin A (IgA) nephropathy develops through a complex 4-hit cascade involving aberrant IgA1 glycosylation, anti-glycan antibody formation, immune complex deposition, and ...
MedPage Today on MSN
Complement inhibitor slowed kidney decline in IgA nephropathy
Continued FDA approval of iptacopan was contingent on 2-year trial data ...
Novartis (SWX:NOVN) reported final two year Phase III results for Fabhalta in IgA nephropathy. Data showed significant long ...
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria ...
In patients with IgA nephropathy, treatment with either sparsentan or irbesartan appears more protective against kidney function decline compared with standard of care treatment. Both sparsentan and ...
Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody, mezagitamab (TAK-079), sustained kidney function up to 18 months after treatment ended in patients with primary immunoglobulin A (IgA) nephropathy, ...
PHILADELPHIA -- Sparsentan (Filspari) outperformed irbesartan in patients with IgA nephropathy over the 2-year phase III PROTECT trial. Over a 110-week treatment period, those on sparsentan had an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results